Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Sanofi-Regeneron's Dupixent wins FDA's nod for 'smoker's lung'
The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a chronic lung disease, commonly known as "smoker's lung", the companies said on Friday.
Sanofi, Regeneron look to seize major opportunity with Dupixent's COPD approval
After more than a decade without any therapeutic advancements in chronic obstructive pulmonary disorder (COPD), people with the progressive disease suddenly have two new options, with more likely o | Regeneron and Sanofi have announced that the FDA has expanded the label of megablockbuster Dupixent to treat COPD.
Regeneron, Sanofi blockbuster Dupixent wins FDA approval for COPD
Dupixent, commonly used to treat eczema and asthma, was cleared for a subset of patients with chronic obstructive pulmonary disease.
Regeneron, Sanofi Get FDA OK for Dupixent to Treat COPD
Regeneron
REGN1.83%increase; green up pointing triangle Pharmaceuticals and Sanofi SAN 0.74%increase; green up pointing triangle have won U.S. Food and Drug Administration expanded approval of their blockbuster anti-inflammatory drug Dupixent in chronic ...
FDA, after delay, clears Regeneron and Sanofi drug for COPD
Dupixent is the first biologic medicine approved in the U.S. for the common lung condition, though competitors from GSK, AstraZeneca and Roche could follow.
Regeneron, Sanofi's Dupixent Get FDA Approval For Chronic Obstructive Pulmonary Disease Treatment
Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY), Friday announced that the U.S. Food and Drug Administration has approved
Regeneron/ Sanofi granted FDA label expansion for Dupixent in COPD
Regeneron (REGN) and Sanofi's (SNY) asthma therapy Dupixent receives FDA approval for label expansion in treating certain patients with COPD. Read more here.
US FDA approves Sanofi-Regeneron's Dupixent for 'smoker's lung'
Sanofi recorded 10.72 billion euros ($11.94 billion) in sales for Dupixent in 2023, which includes Regeneron's share. Analysts on average expect Dupixent, by far Sanofi's best-selling drug, to generate more than 21 billion euros in sales in 2030,
Regeneron, Sanofi Say Dupixent Approved In China To Treat Chronic Obstructive Pulmonary Disease
Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY) Friday said the National Medical Products Administration (NMPA) in China has
Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent
Regeneron stock XX on XX after the company won FDA approval for Dupixent in chronic obstructive pulmonary disease, or COPD.
WNYT NewsChannel 13
1h
Regeneron buys former Quad Graphics site in Saratoga
SARATOGA, N.Y. (WNYT)- Regeneron says they have purchased the sprawling former Quad Graphics site on Duplainville Road in ...
22h
Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors despite daily gains
The stock's rise snapped a four-day losing streak.
FiercePharma
3d
Regeneron's stock drops as it loses bid to block Amgen's Eylea biosimilar
Three months after a federal judge in West Virginia sided with Regeneron, blocking the market entry of two biosimilars for ...
The Saratogian
5h
Regeneron purchases former Quad Graphics site in Saratoga Springs
Regeneron has officially purchased the site of the Quad Graphics building, according to local officials. The Albany Business ...
3h
Regeneron Pharmaceuticals Suffers Worst Month in Two Years After Legal Setback
Regeneron Pharmaceuticals Inc. shares are headed for their biggest monthly drop since mid-2022 after a legal setback that ...
3d
on MSN
Regeneron slump continues as analysts turn more cautious
Regeneron Pharmaceuticals (NASDAQ: REGN) shares are down a further 4% Tuesday, with analysts turning more bearish on the ...
STAT
3d
Pharmalittle: We’re reading about a Regeneron biosimilar fight, a ‘positive surprise’ for Biogen lupus drug, and more
A U.S. judge ruled that Regeneron Pharmaceuticals cannot immediately block U.S. sales of a proposed copy of its blockbuster ...
2d
on MSN
Final Trades: Trane Tech, American Tower, Regeneron and Taiwan Semi
Google reports Microsoft to the European Commission for its practices in the cloud market ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Dupixent
Sanofi
Amgen
Dow Jones Industrial Average
Nasdaq
Feedback